| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
ATHA (ATHA) has 6 insiders with recent SEC Form 4 filings, including 18 buys and 4 sells. ATHA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 329.8K | $2.09M | - | |
| CEO | 40.8K | $280.9K | - | |
| Other | 20.7K | $142.3K | - | |
| Other | 14.0K | $96.2K | - | |
| CFO | 12.9K | $88.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 24, 2024 | Romano Kelly A | - | Buy | 42,400 | $2.36 | $100,050.72 | +46.3% | |
| Jan 5, 2024 | Worthington Mark | General Counsel | Sell | 2,412 | $2.91 | $7,018.92 | -6.5% | |
| Jan 5, 2024 | Litton Mark James | Chief Executive Officer | Sell | 4,820 | $2.91 | $14,026.20 | -3.2% | |
| Jan 5, 2024 | Lenington Rachel | Chief Operating Officer | Sell | 2,412 | $2.91 | $7,018.92 | -15.3% | |
| Dec 29, 2023 | Perceptive Advisors LLC51 | Director, 10% Owner | Buy | 605,686 | $2.42 | $1,462,895.16 | +4.1% | |
| Jun 7, 2023 | Gengos Andrew67 | See Below | Buy | 15,000 | $3.43 | $51,445.01 | +7.5% | |
| Jun 5, 2023 | Gengos Andrew67 | See Below | Buy | 65,012 | $2.95 | $191,572.21 | +35.8% | |
| Mar 30, 2023 | Pickering Grant50 | Director | Buy | 25,000 | $2.41 | $60,350.00 | +216.2% | |
| Mar 29, 2023 | Johnson James A | Director | Buy | 5,000 | $2.40 | $12,000.00 | New | |
| Jan 5, 2023 | Church Kevin | Chief Scientific Officer | Sell | 2,412 | $2.91 | $7,018.92 | -2.9% |